DLRHX Mutual Fund

DLRHX Mutual Fund

NAV$27.15
Do a full portfolio x-ray with DLRHX
Just $25 once·$69/mo·Download sample
Get mine for $25

Fund Essentials - as of Mar 31, 2026

Net Assets
$2M
Expense Ratio
1.46%
Dividend Yield (Current)
10.79%
Holdings
106
Inception Date
Jan 28, 2010
Fund Family
Nomura Asset Management Co Ltd
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually
SEC 30-Day Yield
PRO

Performance

YTD+4.49%
1 Year+31.69%
3 Year+13.40%
5 Year+7.83%
10 Year+10.05%

Asset Allocation

Stocks: 96.77%
Cash: 2.42%
Other: 0.81%
Do a full portfolio x-ray with DLRHX
$25 once. No subscription. Download sample.
Get mine for $25

Top Holdings

View All →
TickerNameWeight
UCB:BRUcb Sa5.90%
REGNRegeneron Pharmaceuticals, Inc.5.46%
PFEPfizer Inc4.84%
GILDGilead Sciences4.40%
ABBVAbbvie Inc.4.09%
Top 10 Concentration: 43.07%Report Date: Mar 31, 2026
Download all 106 holdings for DLRHX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
10.79%
Frequency
Annually
Latest Distribution
$1.48
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO

DLRHX Mutual Fund Overview

DLRHX Mutual Fund (Nomura Healthcare Fund Class R) is managed by Nomura Asset Management Co Ltd with $2.3M in net assets. DLRHX expense ratio is 1.46%, holding 106 positions across sectors including Health Care, Financials, Consumer Staples. Inception date: 2010-01-28.

DLRHX performance shows a YTD return of 4.49%. The 1-year return is 31.69% and the 5-year return is 7.83%. DLRHX dividend yield stands at 10.79%, paid annually.

DLRHX top holdings include Ucb Sa (5.9%), Regeneron Pharmaceuticals, Inc. (5.5%), Pfizer Inc (4.8%), Gilead Sciences (4.4%), Abbvie Inc. (4.1%). Go to all DLRHX holdings, DLRHX sectors, or DLRHX dividends.

DLRHX can be compared against other funds. Use DLRHX overlap to find shared positions, or DLRHX vs another fund for a side-by-side view. DLRHX alternatives are available via the screener, along with tax-loss harvesting opportunities.